Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omecamtiv mecarbil - Cytokinetics

Next Previous
Drug Profile

Omecamtiv mecarbil - Cytokinetics

Alternative Names: AMG-423; CK-1827452; CK-452

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytokinetics
  • Developer Amgen; Cytokinetics; Servier
  • Class Amines; Carboxylic acids; Esters; Fluorobenzenes; Heart failure therapies; Ischaemic heart disorder therapies; Organic chemicals; Piperazines; Pyridines; Small molecules
  • Mechanism of Action Cardiac myosin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Chronic heart failure
  • Phase III Heart failure
  • Phase II Acute heart failure
  • No development reported Angina pectoris; Cardiomyopathies

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Heart-failure(In adolescents, In children, In infants, In neonates) in USA
  • 31 Dec 2024 Cytokinetics entered into termination agreement with Corxel Pharmaceuticals for Omecamtiv mecarbil in Taiwan and China
  • 31 Dec 2024 Cytokinetics has patent protection for Omecamtiv mecarbil covering the composition of matter, the salt form and formulation of Omecamtiv mecarbil in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top